Interleukin-18 in multiple myeloma patients: serum levels in relation to
response to treatment and survival

Alexandrakis, MG
Passam, FH
Sfiridaki, K
Moschandrea, J and
Pappa, C
Liapi, D
Petreli, E
Roussou, P
Kyriakou, DS

Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival

Authors: MG Alexandrakis Passam, FH Sfiridaki, K Moschandrea, J and Pappa, C Liapi, D Petreli, E Roussou, P Kyriakou, DS
Publication date: 1 January 2004
Publisher

Abstract

Interleukin-18 (IL-18) plays a role in the host’s response to tumours and angiogenesis. We determined serum levels of IL-18, vascular endothelial growth factor (VEGF), angiogenin (ANG), tumor necrosis factor (TNF-alpha) and CRP in 65 newly diagnosed myeloma patients. IL-18, VEGF, angiogenin, TNF-alpha and CRP were significantly higher at stage III in comparison to stages 11 and I. These cytokines (measured in 27 patients) significantly decreased after treatment. In survival analysis, higher levels of IL-18 were associated with a poorer prognosis. We conclude that increased serum IL-18 in myeloma patients correlates with advanced disease, increased levels of angiogenic cytokines and worse survival. (C) 2003 Elsevier Ltd. All rights reserved

Similar works

Full text

Available Versions

Pergamos : Unified Institutional Repository / Digital Library Platform of the National and Kapodistrian University of Athens

oai:lib.uoa.gr:uoadl:3090954

Last time updated on 10/02/2023